---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-087756"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2026-08-11T20:00:21+00:00"
generated_at: "2026-08-11T20:01:06.985884+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q2 2026 net income $164K, revenue $869K; explores strategic alternatives

## Summary
- Net income from continuing operations $164K vs $545K in Q2 2025; license revenue $869K vs $952K.
- Total operating expenses $1.7M, up 2.3% YoY on higher G&A and patent write-off.
- Cash and cash equivalents $9.2M as of June 30, 2026.
- Company continues evaluating strategic alternatives including merger, sale, or other transactions; no timetable set.

## SEC filing metadata
- accession: 0001213900-26-087756
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2026-08-11T20:00:21+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000121390026087756/0001213900-26-087756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000121390026087756/ea0298979-8k_therapeu.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-087756
- JSON: https://secwatch.observer/filing/0001213900-26-087756.json
- Plain text: https://secwatch.observer/filing/0001213900-26-087756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.